Discovery and development of anti-angiogenic peptides: A structural link

Ruud P.M. Dings, Irina Nesmelova, Arjan W. Griffioen, Kevin H Mayo

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.

Original languageEnglish (US)
Pages (from-to)83-91
Number of pages9
Issue number2
StatePublished - 2003

Bibliographical note

Funding Information:
This research was supported by grants from the Dutch Cancer Society (to A.W. Griffioen), the Department of Defense DA/DAMD 17-99-1-9564 (to K.H. Mayo) and the National Institutes of Health R01 CA-96090 (to K.H. Mayo).


  • Angiogenesis inhibition
  • Angiostatic peptides
  • Angiostatic proteins
  • Designer peptides and review


Dive into the research topics of 'Discovery and development of anti-angiogenic peptides: A structural link'. Together they form a unique fingerprint.

Cite this